 |
|
|
| |
LONG-TERM (96-WEEK) SAFETY OF FOSTEMSAVIR (FTR) IN
HEAVILY TREATMENT-EXPERIENCED (HTE) ADULTS INFECTED WITH MULTIDRUG-RESISTANT (MDR) HIV-1 (BRIGHTE PHASE 3 STUDY)
|
| |
| |
IAS 2021 July 18-22
Bronagh Shepherd,1 Moti Ramgopal,2 Peter Ackerman,3 Shiven Chabria,3 Fangfang Du,4 Marcia Wang,4 Amy Pierce,5 Andrew Clark6
1GlaxoSmithKline, Uxbridge, UK; 2Midway Specialty Care Center, Fort Pierce, FL, USA; 3ViiV Healthcare, Branford, CT, USA; 4GlaxoSmithKline, Collegeville, PA, USA;
5ViiV Healthcare, Research Triangle Park, NC, USA; 6ViiV Healthcare, Brentford, UK
|
| |
|
|
|
|
|
